Beijing Tiantan Biological Products Corp Ltd (600161) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally.
Total Cash From Operating Activities Chart for Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Corp Ltd (600161) operating cash flow for FY2025 was CNY 375.9M, a -54.1% change from FY2024. Beijing Tiantan Biological Products Corp Ltd's operating cash flow grew from CNY 23.7M in 1998 to CNY 375.9M in 2025 (1485.5% over 27 years). Operating cash flow compound annual growth rate: 5-year CAGR of -11.7%, 10-year CAGR of -2.3%, 20-year CAGR of 5.4%.
Total Cash From Operating Activities (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥24.28B
- Implied Share Price
- ¥12.28
- Enterprise Value
- ¥22.09B
- Revenue (TTM)
- ¥5.65B
- EBITDA
- ¥1.68B
- Profit Margin
- 13.39%
- Trailing P/E
- 32.32
- Forward P/E
- 17.67
- Price/Book (MRQ)
- 2.02
- Price/Sales (TTM)
- 4.30
- EV/EBITDA
- 12.60
- EV/Revenue
- 3.91
- Dividend Yield
- 1.64%
- Book Value
- ¥6.33
- Free Cash Flow (FY2025)
- -¥229.59M
- Free Cash Flow Yield
- -0.95%
Snapshot as of 5th September 2026 — not point-in-time controlled, may lag the live market by a few days.